Annals of Oncology 8:S57-S60, 1997
© 1997 European Society for Medical Oncology
Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
1 Department of Oncology and Hematology, University Hospital Eppendorf Hamburg, Germany
2 Department of Diagnostic Radiology, University Hospital Eppendorf Hamburg, Germany
3 Department of Nuclear Medicine, University Hospital Eppendorf Hamburg, Germany
1Correspondence to: Dr. Maike de Wit Department of Oncology and Hematology Medical Clinic University Hospital Eppendorf D-20246 Hamburg Germany
Background PET using 18fluorodesoxyglucose (FDG) may offer the possibility of differentiating vital from necrotic residual masses.
Patients and methods Seventeen patients with HD and 17 patients with NHL underwent FDG-PET following therapy. According to staging by routine methods at diagnosis, 7 patients presented stage I, 13 stage II, 5 stage III, and 9 stage IV. A dose of 250–400 MBq FDG was injected and whole-body PET was performed 30–60 minutes later.
Results Residual mass was found in 32 patients with routine methods. FDG-PET was negative in 17 patients, who were considered to be in CR. None of them relapsed (median follow-up 63 weeks). FDG-PET was positive in 17 patients. Sixteen patients had residual mass with routine methods. Four patients received radiation after PET. Their median follow-up is 58 weeks without relapse. Two other patients with lasting CR had FDG uptake outside the residual mass - one with confirmed pneurnonia. Five patients had histologically confirmed lymphoma, 2 patients relapsed according to routine methods. One patient is likely to be false positive because of fracture at lymphoma site. Seven of 10 patients with FDG uptake in the residual mass after completed therapy relapsed. According to routine restaging, 2 patients achieved CR. In 1 patient an additional focus was found in the humerus in spite of normal scintigraphy with histologically confirmed lymphoma. There were no false-negative results, but 3 false-positive results inside and 2 false-positive results outside the residual mass after completed therapy.
Conclusions PET performed for evaluation of residual mass after treatment of lymphoma has a high predictive value.
lymphoma, positron emission tomography, residual mass, 18-fluorodeoxyglucose (FDG)
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein Imaging in staging of malignant lymphoma: a systematic review Blood, January 15, 2008; 111(2): 504 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Thomas, T. de Groot, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, and G. Verhoef Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann. Onc., September 1, 2002; 13(9): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Spaepen, S. Stroobants, P. Dupont, S. Van Steenweghen, J. Thomas, P. Vandenberghe, L. Vanuytsel, G. Bormans, J. Balzarini, C. De Wolf-Peeters, et al. Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods? J. Clin. Oncol., January 15, 2001; 19(2): 414 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jerusalem, Y. Beguin, M.F. Fassotte, F. Najjar, P. Paulus, P. Rigo, and G. Fillet Whole-Body Positron Emission Tomography Using 18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin's Disease and Non-Hodgkin's Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging Blood, July 15, 1999; 94(2): 429 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]
|
|